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Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer,
cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3,
4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in
human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating
and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using
flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse
transcriptase–polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were
negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity
in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin
analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10
 10–10
 6 M: 48.5–70.2% inhibition;
SOM230 10
 9–10
 6 M: 44.9–65.4% inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in
proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues
suggest that these receptors may have a role in angiogenesis.
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Angiogenesis is a carefully regulated normal physiologic process,
required for wound healing, reproduction and development
(Griffioen and Molema, 2000). Vascular endothelial cells are
normally quiescent cells, dividing every 2–5 years (Woltering et al,
1997). However, endothelial cell stimulation by proangiogenic
factors and cytokines from inflammatory cells or tumours results
in their proliferation with an altered expression profile (Fox et al,
2001).
Somatostatin is a widely distributed inhibitory polypeptide that
inhibits exocrine secretion, cellular proliferation and cellular
differentiation, and promotes apoptosis. The effects of Somato-
statin and its analogues are mediated via five G-protein-linked
receptors (sst 1, 2, 3, 4, 5). These receptors act through multiple
signal transduction pathways to elicit their inhibitory effects.
Proliferating endothelium in vitro express sst 2 that is also
expressed by endothelial cells within or adjacent to tumours
(Reubi et al, 1994, 1996, 2001; ten Bokum et al, 1999, Watson et al,
2001; Koizumi et al, 2002), and it has been shown that sst 2 is
expressed in the angiogenic sprouts of endothelium from placental
veins (Watson et al, 2001). Experimental angiogenesis has been
inhibited by the synthetic sst analogue Octreotide (Woltering et al,
1991; Danesi and Del Tacca, 1996; Danesi et al, 1997) that has a
high affinity for sst 2. Human umbilical vein endothelial cells
(HUVECs), which are widely used as an endothelial cell model in
vitro, have also been shown to express sst 2 (Curtis et al, 2000).
Sst 1 has previously been detected in HUVECs (Curtis et al,
2000), and in the endothelium of neuroblastomas (Albers et al,
2000) and benign and malignant ovarian tumours (Hall et al, 2002).
Sst 3 expression has also been demonstrated in HUVECs (Jia et al,
2003), and in the endothelial cell line Eahy926 (Florio et al,
2003). Sst 4 has only been reported in HUVECs (Curtis et al, 2000).
There are currently no reports in the literature indicating that
sst 1, 3 or 4 expression is unique to proliferating vessels. The
expression of sst 5 in primary human endothelial cells remains
unreported.
Therefore, with the knowledge of the selective expression of sst 2
in proliferating endothelial cells, the aim of these studies was to
determine whether there was a change in sst 1, 3, 4 and 5 expres-
sion in proliferating vs quiescent human umbilical endothelial
cells in vitro.
MATERIALS AND METHODS
HUVEC isolation and culture
Human umbilical cords were obtained from Hull Maternity
Hospital with permission from the local ethics committee and
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sinformed patient consent. HUVECs were harvested by collagenase
digestion, according to the method by Jaffe et al (1973). Reagents
were purchased from Invitrogen (Paisley, UK), unless otherwise
stated. Cells were routinely cultured in D-MEM with 5mM
D-glucose supplemented with 20% foetal bovine serum (FBS),
20ngml
 1 human b-endothelial cell growth factor (Sigma, Poole,
UK), 8Uml
 1 heparin sodium salt (Sigma), 2mML -glutamine,
50Uml
 1 penicillin G and 50mgml
 1 streptomycin sulphate.
Culture vessels were coated in 1% gelatin (Sigma) for 10min prior
to use. The HUVECs were grown at 371C with 5% CO2 in a
humidified environment. Immunohistochemical detection of von
Willebrand factor confirmed that the cells were of endothelial
origin. Cells were passaged at a ratio of 1:3 after reaching 80–90%
confluence, and media were replenished every 48h.
Establishment of proliferating and quiescent HUVECs
In all, 14 separate HUVECs lines derived from different patients
were seeded into six-well plates at a density of 10
5 cellswell
 1 in
2ml of medium. Cells that approximately doubled in number
within 24h, as determined by microscopic examination, were
tentatively identified as proliferating cells. Quiescent cells were left
to grow until confluent and then the medium was replaced with
growth factor-free medium for 24h. Growth factor-free medium
lacked ECGF and heparin sodium salt, and FBS was replaced with
charcoal-stripped FBS. The viability of quiescent cells was
demonstrated by passaging them at a 1:2 ratio after 48h growth
factor deprivation, and then confirming that they grew to
confluence again within 48h. The proliferative status of the cells
was confirmed using cell cycle analysis as described below. Nine of
the lines of proliferating and quiescent HUVECs were grown in
triplicate for RNA extraction. The three lines were used for cell
cycle analysis alone, one line was used for the immunohisto-
chemistry and another to determine the effects of the somatostatin
analogues Octreotide and SOM230 on HUVEC proliferation.
HUVEC cell cycle analysis
Propidium-iodide-stained samples were analysed for cell cycle
distribution as described previously (Newton et al, 2003). Briefly,
HUVECs from six-well plates were centrifuged at 200g for 10min,
resuspended in 300ml phosphate-buffered saline (PBS) and then
fixed in 70% ice-cold ethanol overnight. The cells were recovered
by centrifugation, and resuspended in 250ml of PBS to which 10ml
of 0.5mgml
 1 propidium iodide solution was added. Following the
addition of propidium iodide, the samples underwent incubation
for 30min at 371C. Samples were analysed with a FACS
CALIBUR flow
cytometer (Becton Dickinson, Cowley, UK) with an argon laser
tuned to 488nm. Forward and orthogonal light scatter and red
fluorescence (FL-2) were then determined from at least 10000
events. Histogram plots were analysed using the cell cycle analysis
software, Modfit (Becton Dickinson).
Quantitative reverse transcriptase–real-time polymerase
chain reaction (qRT–PCR)
Primer sets were then submitted to a BLAST search at http://
www.ncbi.nlm.nih.gov/BLAST/ to confirm their uniqueness. The
specificity of each primer set was confirmed in the results for the
relative expression of sst in proliferating and quiescent HUVECs,
where the detection of any one sst does not depend on the
detection of another. RNA was extracted from HUVECs grown in
six-well plates using Trizol (Invitrogen), as directed. Since sst are
intronless, RNA from each sample was treated with deoxyribonu-
clease I (Invitrogen) to remove contaminating genomic DNA prior
to reverse transcription, in the presence of RNAsin ribonuclease
inhibitor (Promega UK Ltd, Southampton, UK). The RNA was
reverse transcribed with Moloney murine leukaemia virus reverse
transcriptase using random primers (Invitrogen), according to the
manufacturer’s instructions. qRT–PCR was performed utilising
the ABI prism 5700 sequence detection system (Applied Biosys-
tems, Warrington, UK). Sst 1–5 oligonucleotide forward primers,
reverse primers and internal probes were designed using Primer
Express version 1.0 (Applied Biosystems), and synthesised by
MWG-Biotech (Ebersberg, Germany). The internal probes were
labelled at the 50-ends with the reporter fluorochrome 6-
carboxyfluorescein and at the 30-ends with the quencher fluor-
ochrome 6-carboxytetramethylrhodamine. These primers and
probes are detailed in Table 1. Each reaction volume was 25ml,
and contained 1 TaqMan Universal Master Mix (Applied
Biosystems), 5ml cDNA, 300nM forward primer, 300nM reverse
primer and 150nM internal probe. Amplification of the human
b-glucoronidase housekeeping gene (Applied Biosystems) was used
as an internal standard. Water was used as a nontemplate control.
Nonreverse-transcribed samples were run in parallel to confirm
that positive results were not due to amplification of genomic
DNA. Human genomic DNA was used as a positive control for all
sst. The PCR cycle consisted of an initial cycle of 501C for 2min
followed by 951C for 10min, and then 50 repeated cycles of 951C
for 15s (denaturation) and 601C for 1min (primer annealing and
Table 1 Sst 1, 2, 3, 4, 5 oligonucleotide forward primers, reverse primers and internal probes
SSTR 1 Forward primer 50-GCTCGGAGCGCAAGATCA-30
Reverse primer 50-CGTCGTCCTGCTCAGCAAA-30
Probe 50-CTTAATGGTGATGATGGTGGTGATGGTGTTT-30
SSTR 2 Forward primer 50-TGGTCCACTGGCCCTTTG –30
Reverse primer 50-TTGATGCCATCCACAGTCATG-30
Probe 50-CAAGGCCATTTGCCGGGTGG-30
SSTR 3 Forward primer 50-TGGGCCTGCTGGACTC-30
Reverse primer 50-GTTGAGGATGTAGACGTTGGTGACT-30
Probe 50-CCGTGTGCCGCAGGACCACA-30
SSTR 4 Forward primer 50-GCGCTCGGAGAAGAAAATCA-30
Reverse primer 50-GGCTGGTCACGACGAGGTT-30
Probe 50-CGTCTTTGTGCTCTGCTGGATGCCTT-30
SSTR 5 Forward primer 50-TCATCCTCTCCTACGCCAACA-30
Reverse primer 50-TGGAAGCTCTGGCGGAAGT-30
Probe 50-CCGTCCTCTCAGGCTTCCTCTCGGA-30
Sst¼somatostatin; SSTR¼somatostatin receptor.
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sextension). Proliferating and quiescent HUVECs that were to be
compared were assayed simultaneously to ensure accurate relative
quantification as described previously (Green et al, 2002).
Immunohistochemistry
Proliferating and quiescent cells were cultured as above in Labtec
chamber slides in quadruplicate (Nunc, Wiesbaden, Germany).
The media were removed and the cells were fixed in 95% ice-cold
ethanol for 60min, followed by washing in PBS three times.
Immunocytochemistry was performed for sst 2 and 5 as detailed
previously (Stafford et al, 2004). Briefly, nonspecific binding sites
were blocked with an Avidin/Biotin Blocking Kit (Vector Ltd, UK)
and nonspecific serum protein block and endogenous peroxidase
activity was quenched by incubating the cells with 1% H2O2.
Rabbit monoclonal antibodies to sst 2 and 5 were obtained from
Gramsch Laboratories (Schwabhausen, Germany). Sections were
then incubated overnight at 41C with primary antibody, diluted to
1:10000 in PBS plus 1% bovine serum albumin and 0.3% Triton
X-100.
Signal from the bound primary antibody was then amplified and
visualised using the DAKO Catalysed Signal Amplification
Peroxidase System K1500 (Dako, High Wycombe, Bucks, UK).
The streptavidin/biotin complex was applied and signal amplified
by adding the amplification reagent prior to streptavidin
peroxidase. Immunoreactivity was then visualised by adding
hydrogen peroxide as the enzyme substrate, in the presence of
0.05% 3,30-diaminobenzidine. Signal was intensified with copper
sulphate and nuclei lightly counterstained with Harris haema-
toxylin, before rehydrating and mounting with DPX.
Samples of anterior pituitary and normal pancreas known to
express the relevant antigen were used as positive controls.
Negative controls included omission of the primary antibody and
incubation with 1% nonimmune serum.
Effect of the somatostatin analogues Octreotide and
SOM230
To determine whether sst may be functionally important in
proliferation, dose–response curves were constructed with the
somatostatin analogues Octreotide and SOM230 (a gift from
Novartis Ltd, Basle, Switzerland). Octreotide is a somatostatin
analogue in clinical practice that has affinity for sst 2 and 5
(0.3870.08 and 6.371.0 IC50 (nM)7s.e.m., respectively), while
SOM230 is an experimental multiligand receptor analogue that has
affinity for sst 1, 2, 3 and 5 (9.370.1, 1.070.1, 1.5703 and
0.1670.01 IC50 (nM)7s.e.m., respectively). HUVEC proliferation
was assessed using the WST-1 proliferation assay (Roche, Lewes,
UK). HUVECs were aliquoted into gelatin-coated 96-well culture
plates at a density of 2500 cells well
 1. After 18h incubation, the
medium was replaced with fresh medium containing 20%
charcoal-stripped FBS, and excluding regular FBS and ECGF. At
6h after the medium was switched, HUVECs were treated with
10
 6–10
 10 M SOM230 and Octreotide in parallel for 21h. For the
final 3h of incubation, WST-1 was added to each well according to
the manufacturer’s instructions, and absorbance measured hourly
for 3h, at a wavelength of 450nm with a reference wavelength of
620nm using an Anthos 2010 plate reader (Anthos-Labtec,
Salzburg, Austria). To ensure that sst 5 was expressed under these
conditions, immunostaining for sst 5 was undertaken and shown
to be positive. Six replicates were performed for each point of the
dose–response curves.
Statistical analysis
The data were analysed with SPSS 11.5 (SPSS Science, Chicago, IL,
USA). The proportion of HUVECs in each phase of the cell cycle
was compared between proliferating and quiescent samples using
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Figure 1 Flow cytometry for cell cycle parameters of propidium–iodide-
stained samples of (A) proliferative, and (B) quiescent HUVECs. This was
performed in triplicate for cells derived from each patient.
Table 2 Expression of sst 1, 2 and 5 in proliferating and quiescent
HUVECs, including relative expression of sst 2 and 5
Receptor
SSTR 1 SSTR 2 SSTR 3 SSTR 5
Patient P Q P Q P Q P Q
1   ++    ++  
2+ + +      +  
3+ + +         
4+ + +         
5+ + +      +  
6+            
7    +   +   +  
8   +        +  
9    100743.0% 12.278.5%    100710.7% 1.171.4%
P¼proliferative; Q¼quiescent; HUVEC¼human umbilical vein endothelial cell;
SSTR¼somatostatin receptor. Experiments were performed for six replicates on
each of the cultures derived from the nine patients. Relative sst gene expression is
displayed as a percentage of the corresponding proliferative cells. Each quantified
value is expressed as mean7s.d.
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sthe unpaired t-test. The expression of sst was compared between
proliferating and quiescent samples using the Mann–Whitney
U-test. P-values o0.05 were considered statistically significant.
Data from the WST-1 proliferation assay were analysed using
ANOVA with post hoc Dunnett’s pairwise multiple comparison
t-tests. P-values o0.05 were considered statistically significant.
RESULTS
Cell cycle analysis of proliferating and quiescent HUVECs
Quiescent cells demonstrated reduced cell cycle progression in
comparison to the corresponding proliferating cells (Figure 1). The
proportion of quiescent cells in the S phase of the cell cycle
distribution was significantly lower than that of the corresponding
proliferating cells (reduced by 18.175.8–43.872.4%; Po0.05;
Figure 1). Additionally, significantly more quiescent endothelial
cells were distributed in the G0–G1 phases (increased by
31.972.5–73.173.2%; Po0.05; Figure 1). This indicated that
HUVECs subjected to 24h growth factor deprivation were
prevented from progressing from G0–G1 to S phase. This validated
our protocol for the establishment of proliferating and quiescent
endothelial cell cultures.
qRT–PCR of proliferating and quiescent HUVECs
Sst 2 and 5 were preferentially expressed in proliferating cultures
(Table 2). There appeared to be no relationship between cell cycle
progression and sst 1 or 3 expression (Table 2); therefore, these sst
were not quantified. Only one of the quiescent cultures was
positive for sst 2, and the expression of sst 2 in this sample was
significantly lower than that of the corresponding proliferating
culture (Po0.01). The quiescent culture from this sample was also
positive for sst 5, and again, the expression was significantly
reduced (Po0.01). Considering that all other quiescent samples
were negative for sst 2 and 5, it is possible that this sample
contained proliferating cells. Most of the proliferating samples
coexpressed at least two receptors, and sst 2 was always
coexpressed with at least one other receptor. Sst 1 and 5 were
only expressed simultaneously if sst 2 was also expressed. All
samples were negative for sst 4.
Immunohistochemistry
Sst 2 and 5 receptor positivity was seen in all proliferating but not
quiescent HUVEC culture (Figure 2A and C, quiescent cells are
negative for sst 2 and sst 5, respectively; Figure 2B and D, uniform
immunopositivity for sst 2 and 5 in the proliferating cells).
Figure 2 Immunohistochemistry: immunostaining was performed in cultures on chamber slides in quadruplicate. (A) Quiescent cells are negative for sst 2
positivity; (B) uniform immunopositivity for sst 2 in the proliferating cells; (C) quiescent cells are negative for sst 5 positivity; and (D) uniform
immunopositivity for sst 5 in the proliferating cells (magnification  10).
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sEffect of Octreotide and SOM230 on HUVEC proliferation
Octreotide significantly inhibited HUVEC proliferation across the
concentration range 10
 10–10
 6 M (48.577.3–70.270.4% inhibi-
tion), while SOM230 significantly inhibited HUVEC proliferation
across the concentration range 10
 9–10
6 M (44.979.2–65.476.1%
inhibition) in a dose-dependent manner (Figure 3).
DISCUSSION
We have identified that sst 2 and 5 are preferentially expressed in
the proliferating phenotype in HUVECs, and that a proportion of
HUVECs express sst 1 and 3, irrespective of proliferative status.
Our results support previous in vivo and in vitro findings on the
preferential expression of sst 2 in activated endothelial cells (Reubi
et al, 1994, 1996, 2001; ten Bokum et al, 1999; Koizumi et al, 2002).
The finding that both sst 5 mRNA and positive immunostaining
for sst 5 were expressed in HUVECs, and altered with proliferative
status, is novel and indicates that both the mRNA and the protein
are expressed in proliferation. Sst 5 has not been specifically
reported in vessels surrounding tissues with characteristic
neovascularisation. In tumours, however, the presence of mRNA
for sst 2, sst 5, or for both, has positively correlated with
125I-
[Tyr
3]-Octreotide binding sites. In 1998, Siehler et al suggested
that
125I-[Tyr
3]-Octreotide binding is frequently attributable to sst
5. Considering that
125I-[Tyr
3]-Octreotide has high affinity for sst 2
and moderate affinity for sst 5, it is probable that Octreotide
binding previously reported in peritumoral vessels may have been
partially due to the presence of sst 5, in accordance with our
findings in HUVECs. Sst 5 is preferentially expressed in mitogen-
stimulated human T-lymphocytes (Ghamrawy et al, 1999), and we
have now shown that this preferential expression extends to
endothelial cells. Vapreotide (an analogue with sst 2 and 5 activity)
has been shown to inhibit proliferation of CCK-stimulated CHO
cells, which expressed endogenous CCK receptors and that were
transfected with sst 5. The effects of sst 5 appeared to be due to the
inhibition of guanylate cyclase, and a consequent reduction in
cyclic GMP formation, which modulated the activation of the
MAPK cascade (Cordelier P et al, 1997). As MAP kinase activation
is associated with proliferation of endothelial cells (Bogatcheva
et al, 2003; Pintus G et al, 2003), its inhibition may potentially be
the mechanism by which sst 5 activation may have an
antiproliferative action.
The finding that HUVEC proliferation was inhibited by both
Octreotide and SOM230 indicates the likelihood that sst 2 and 5 are
functional in the proliferation of these endothelial cells. However,
as both Octreotide and SOM230 have both sst 2 and 5 activities, it
is unclear whether it is activation of either or both that is causing
the inhibition of proliferation. The recent development of a new
generation of somatostatin analogues that target different receptor
combinations (Lamberts et al, 2002) will aid in further character-
isation of the role of sst in the endothelium.
Despite much evidence of the antiproliferative effects of
sst 2 activation, the clinical use of Octreotide as an antineoplastic
agent has been disappointing (Hejna et al, 2002). This may in
part be due to the presence of sst 5 on peritumoral vessels.
Recently, Zatelli et al (2001) showed that sst 5 agonists can inhibit
the antiproliferative activity of sst 2 agonists in the human
medullary thyroid carcinoma cell line TT. Sst 2 and sst 5 exert
antiproliferative effects in the pituitary cell line AtT-20 via similar
mechanisms (Tallent et al, 1996), yet in CHO cells, the two
receptors exert their antiproliferative effects via different mechan-
isms (Buscail et al, 1995). This suggests that the effects of
coactivation of sst 2 and 5 are highly tissue specific, and perhaps
the antiproliferative effects of sst 2 are antagonised by sst 5 in the
endothelium.
We have also shown that HUVECs express sst 1 irrespective of
proliferative status. The expression of sst 1 in both proliferating
and quiescent endothelium, however, does not eliminate sst 1 as a
suitable therapeutic target. In CHO-K1 cells, sst 1 induces
cytostatic effects by modulating the MAP kinase pathway (Florio
et al, 2000). Also, Buchan et al (2002) have shown that activation of
sst 1 inhibits endothelial cell migration. There has been no
evidence to date, however, that sst 1 induces apoptosis. The
activation of endothelial sst 1 may therefore inhibit cell migration
and induce cytostatic effects in proliferating endothelial cells,
without inducing apoptosis in quiescent cells. The expression of sst
1 in quiescent cells also suggests that sst 1 may have other roles in
endothelial functions that are not associated with cell cycle
progression.
Our results also show that HUVECs express sst 3, in accordance
with the findings of Jia et al (2003). Only two of our samples,
however, expressed this receptor subtype. Florio et al (2003) found
that sst inhibits DNA synthesis in the sst 3-expressing endothelial
cell line Eahy926, and that this effect was blocked by a sst 3
subtype-specific antagonist.
We observed high variability in the coexpression of sst by
proliferating HUVECs.
Coexpression of sst 2 and 5 occurred in five of nine proliferat-
ing samples. Also, two of nine proliferating samples expressed
sst 2 when sst 5 was absent, and one of nine expressed sst 5 when
sst 2 was absent. It is possible that there is variation in the
temporal expression of sst in HUVECs derived from different
sources, and that coexpression of sst 2 and 5 may transiently
occur in more samples than is indicated in this study. The cause
of this variability is unclear; a similar phenomenon occurs
in the immunocytohistochemical detection of sst in tumour
vessels from different patients (Reubi et al, 1994). Inconsistencies
in sst expression are not unique to the endothelium, and variation
is evident in a wide range of normal and neoplastic tissues
(Hofland and Lamberts, 2001; Reubi et al, 2001). This high
variability in the coexpression of endothelial sst may be of
particular importance in the clinical application of sst analogue
therapy.
Effect of octreotide and SOM230 on HUVEC proliferation 
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Figure 3 Effect of Octreotide and SOM230 on HUVEC proliferation in
growth factor-free conditions. Octreotide significantly inhibited HUVEC
proliferation across the concentration range 10
 10–10
 6 M (48.577.3–
70.270.4% inhibition), while SOM230 significantly inhibited HUVEC
proliferation across the concentration range 10
 9–10
 6 M (44.979.2–
65.476.1% inhibition) in a dose-dependent manner. Effects on prolifera-
tion were determined using the WST-1 proliferation assay. Data are
expressed as mean7s.e.m., determined from six replicates. **Po0.01,
*Po0.05.
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sOverall, these data show that sst may have a functional role in
angiogenesis with dynamic changes in sst 2 and 5 expression during
proliferation and inhibition of proliferation by the analogues that
have sst 2 and 5 activity. Further characterisation of the role of
endogenous sst and its receptors in modulating endothelial function
in other endothelial cell models may define their role further.
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